SYRACUSE, NY (August 16, 2018) — New research suggests that shifts in the bacteria within a child's mouth could provide objective biomarkers for identifying autism spectrum disorder. The findings of this research, conducted by scientists from Penn State Medical Center, SUNY Upstate Medical University, and Quadrant Biosciences, Inc., catalyze development of a novel, saliva-based panel to aid clinicians in the early diagnosis of autism spectrum disorder. The new study, "Oral Microbe Activity in Autism," was published online by the journal Autism Research.
Previous research has suggested that bacteria living in the gastrointestinal (GI) tract may influence autistic behavior. Moreover, autism spectrum disorder (ASD) is associated with several abnormalities related to the mouth and throat, including taste and texture aversions, speech difficulties and salivary transcriptome alterations.
"There is mounting evidence that the GI microbiome is disrupted in children with ASD, and this study shows that this disruption may extend to the mouth and throat. It appears that gene expression activity within oral microbial communities is altered in children with autism spectrum disorder," said Steven Hicks, MD, Ph.D., of Penn State Hershey, lead investigator on the project. "The shifts in microbial populations were associated with ASD co-morbidities such as GI disturbances, as well as social and repetitive behaviors. This research suggests that measuring activity of these microbial populations in saliva may provide objective biomarkers to aid in the clinical evaluation of ASD."
In this study, researchers identified changes in the salivary microbiome of 346 children aged 2-6 years across three developmental profiles: ASD (n=180), non-autistic developmental delay (DD) (n=60), and typically developing children (TD) (n=106). Saliva was collected via cheek swab from each study participant. RNA from actively transcribing microbes was sequenced, quantified and analyzed across the three groups of children. ASD children with and without GI disturbances were also compared. The researchers found 12 groups of microbes to be altered between the development status groups and identified 28 groups that distinguished ASD patients with and without GI disturbances. Five ratios of microbes distinguished ASD from TD children (79.5% accuracy), three distinguished ASD from DD (76.5% accuracy), and three distinguished ASD children with/without GI disturbance (85.7% accuracy). Interestingly, the microbial gene expression patterns associated with autism were implicated in energy processing.
"The underlying association of specific microbial population shifts with ASD status will require further study, but may result from alterations of microbial metabolism, or through pathogenic microbial-host relationships," said Frank Middleton, Ph.D., study co-investigator from SUNY Upstate Medical University. "We saw significant differences in gene expression in these organisms that were associated with lysine degradation, an important building block in neurotransmitter production."
Richard Uhlig, Founder and Chief Executive Officer of Quadrant Biosciences and one of the co-authors of the study, noted that Quadrant is developing a saliva-based biomarker panel to aid clinicians in the earlier diagnosis of ASD. "These research findings have been fundamental in our ongoing efforts to develop a biomarker panel that can provide clinicians and parents with more confidence in the diagnosis of ASD. Examining microbial activity will be a crucial element of the panel," he said. "Our aim is to offer a molecular diagnostic that can provide objective support for the diagnosis of ASD as early as possible, when treatment is most efficacious."
###
About Quadrant Biosciences
Quadrant Biosciences, Inc. is developing clinical assessment and molecular diagnostic tools to help physicians assess brain health and support more rapid accurate diagnoses of brain-based disorders. The company's tests are expected to improve the diagnosis, monitoring and treatment of serious health conditions including autism spectrum disorder, concussion and Parkinson's disease. Quadrant is collaborating with leading research institutions and hospitals to develop novel saliva-based tests that measure epigenetic biomarkers related to gene expression patterns underlying these disorders. Current products include the FDA-compliant ClearEdge® toolkit for functional assessment of neurological disorders, and the Clarifi™ epigenetic biomarker panel in development to aim clinicians in the diagnosis of autism spectrum disorder. Quadrant Biosciences is a participant in START-UP NY, a New York State economic development program. For more information about the company, contact [email protected] or visit our website at http://www.QuadrantBiosciences.com.
Contacts:
Quadrant Biosciences:
Richard Uhlig
Founder and CEO
Quadrant Biosciences Inc.
[email protected]
For Media:
Bioscribe, Inc.
Joan Kureczka
[email protected]
(415) 821-2413
Or
Nicole Litchfield
[email protected]
Media Contact
Joan Kureczka
[email protected]
415-690-0210
http://dx.doi.org/10.1002/aur.1972
